About: The hazard of (sub)therapeutic doses of anticoagulants in non‐critically ill patients with Covid‐19: the Padua province experience

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: The hazard of (sub)therapeutic doses of anticoagulants in non‐critically ill patients with Covid‐19: the Padua province experience Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	The hazard of (sub)therapeutic doses of anticoagulants in non‐critically ill patients with Covid‐19: the Padua province experience
Creator	Avogaro, Angelo Capone, Federico Ceccato, D Ceccato, Davide Cipriani, Alberto Criveller, Pietro Fioretto, Paola Frigo, Annachiara Gemelli, Marco Gorgi, Davide Leone, Lucia Marchese, Giuseppe Monticelli, Jacopo Pagano, Claudio Pasquetto, Giampaolo Pesavento, Raffaele Pesavento, ¶ Postal, Anna Prandoni^, Paolo Rossato, Marco Saller, Alois Sarais, Cristiano Simioni, Paolo Vettor, Roberto
source	Medline; PMC
abstract	BACKGROUND: COVID‐19 is responsible for a worldwide pandemic, with a high rate of morbidity and mortality. The increasing evidence of an associated relevant pro‐thrombotic coagulopathy has resulted in an increasing use of antithrombotic doses higher than usual in COVID‐19 patients. Information on the benefit/risk ratio of this approach is still lacking. OBJECTIVE: to assess the incidence of relevant bleeding complications in association with the antithrombotic strategy, and its relationship with the amount of drug. METHODS: Consecutive COVID‐19 patients admitted between February and April 2020 were included in a retrospective analysis. Major bleedings (MB) and clinical relevant non‐major bleeding (CRNMB) were obtained from patient medical records and were adjudicated by an independent committee. RESULTS: Of the 324 patients who were recruited, 240 had been treated with prophylactic doses and 84 with higher doses of anticoagulants. The rate of the composite endpoint of MB or CRNMB was 6.9 per 100 person/months in patients who had been given prophylactic doses, and 26.4 per 100 persons/months in those who had been prescribed higher doses (HR 3.89; 95%CI, 1.90 to 7.97). The corresponding rates for overall mortality were 12.2 and 20.1 per 100 person/months, respectively. CONCLUSIONS: The rate of relevant bleeding events were high in patients treated with (sub)therapeutic doses of anticoagulants. In the latter group, overall mortality did not differ from that of patients treated with standard prophylactic doses and was even higher. Our result does not support a strategy of giving (sub)therapeutic doses of anticoagulants in non‐critically ill patients with COVID‐19.
has issue date	2020-07-21(xsd:dateTime)
bibo:doi	10.1111/jth.15022
bibo:pmid	32692874
has license	no-cc
sha1sum (hex)	11b6bff0fe24b7ac3ac6388cfa94e2de68af5500
schema:url	https://doi.org/10.1111/jth.15022
resource representing a document's title	The hazard of (sub)therapeutic doses of anticoagulants in non‐critically ill patients with Covid‐19: the Padua province experience
has PubMed Central identifier	PMC7404507
has PubMed identifier	32692874
schema:publication	J Thromb Haemost
resource representing a document's body	covid:11b6bff0fe24b7ac3ac6388cfa94e2de68af5500#body_text
is schema:about of	named entity 'Covid-19' covid:arg/11b6bff0fe24b7ac3ac6388cfa94e2de68af5500 named entity 'anticoagulants' named entity 'Covid-19' named entity 'anticoagulants' named entity 'critically ill patients' named entity 'WHO' named entity 'statistically significant' named entity 'thrombotic complications' named entity 'comorbidities' named entity 'clinically relevant' named entity 'VTE' named entity 'Cox regression' named entity 'thrombotic complications' named entity 'D-dimer' named entity 'prophylactic' named entity 'respiratory symptoms' named entity 'COVID' named entity 'ICU' named entity 'SARS-CoV-2' named entity 'risk factors' named entity 'Declaration of Helsinki' named entity 'antithrombotic' named entity 'macrolides' named entity 'infection' named entity 'antithrombotic agents' named entity 'pharyngeal' named entity 'morbidity' named entity 'unfractionated heparin' named entity 'antithrombotic' named entity 'diagnostic criteria' named entity 'pulmonary embolism' named entity 'SAS Institute Inc.' named entity 'thromboembolic' named entity 'thrombophilia' named entity 'lung' named entity 'antithrombotic' named entity 'fondaparinux' named entity 'D-dimer' named entity 'Cary, NC' named entity '15,000' named entity 'flu-like syndrome' named entity 'anticoagulants' named entity 'anticoagulant' named entity 'D-dimer' named entity 'antiviral agents' named entity 'major bleeding' named entity 'thrombosis' named entity 'dual antiplatelet therapy' named entity 'prophylaxis' named entity 'Covid-19' named entity 'anticoagulant' named entity 'retrospective study' named entity 'disease outbreak' named entity 'cardiovascular disorders' named entity 'plasma levels' named entity 'intensive care' named entity 'retrospective cohort study'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software